Alterations of lipid metabolism provide serologic biomarkers for the detection of asymptomatic versus symptomatic COVID-19 patients.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 07 2021
09 07 2021
Historique:
received:
04
03
2021
accepted:
01
07
2021
entrez:
10
7
2021
pubmed:
11
7
2021
medline:
20
7
2021
Statut:
epublish
Résumé
COVID-19 pandemic exerts a health care emergency around the world. The illness severity is heterogeneous. It is mostly unknown why some individuals who are positive for SARS-CoV-2 antibodies stay asymptomatic while others show moderate to severe disease symptoms. Reliable biomarkers for early detection of the disease are urgently needed to attenuate the virus's spread and help make early treatment decisions. Bioactive sphingolipids play a crucial role in the regulation of viral infections and pro-inflammatory responses involved in the severity of COVID-19. However, any roles of sphingolipids in COVID-19 development or detection remain unknown. In this study, lipidomics measurement of serum sphingolipids demonstrated that reduced sphingosine levels are highly associated with the development of symptomatic COVID-19 in the majority (99.24%) SARS-CoV-2-infected patients compared to asymptomatic counterparts. The majority of asymptomatic individuals (73%) exhibited increased acid ceramidase (AC) in their serum, measured by Western blotting, consistent with elevated sphingosine levels compared to SARS-CoV-2 antibody negative controls. AC protein was also reduced in almost all of the symptomatic patients' serum, linked to reduced sphingosine levels, measured in longitudinal acute or convalescent COVID-19 samples. Thus, reduced sphingosine levels provide a sensitive and selective serologic biomarker for the early identification of asymptomatic versus symptomatic COVID-19 patients.
Identifiants
pubmed: 34244584
doi: 10.1038/s41598-021-93857-7
pii: 10.1038/s41598-021-93857-7
pmc: PMC8270895
doi:
Substances chimiques
Biomarkers
0
Sphingolipids
0
ASAH1 protein, human
EC 3.5.1.23
Acid Ceramidase
EC 3.5.1.23
Sphingosine
NGZ37HRE42
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
14232Subventions
Organisme : NCI NIH HHS
ID : P01 CA203628
Pays : United States
Organisme : NIGMS NIH HHS
ID : R25 GM113278
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA250458
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001450
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE016572
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA236379
Pays : United States
Organisme : NCI NIH HHS
ID : CA214641
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK123704
Pays : United States
Organisme : NIDCR NIH HHS
ID : DE016572
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM132055
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
J Neurol Sci. 2020 Sep 15;416:117011
pubmed: 32650143
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
J Med Virol. 2021 May;93(5):2591-2594
pubmed: 33480063
J Allergy Clin Immunol. 2020 Sep;146(3):518-534.e1
pubmed: 32896310
Immunity. 2020 Jul 14;53(1):19-25
pubmed: 32610079
JAMA. 2020 Aug 18;324(7):663-673
pubmed: 32706371
Nat Rev Cancer. 2018 Jan;18(1):33-50
pubmed: 29147025
J Endocrinol Invest. 2020 Aug;43(8):1167-1168
pubmed: 32468512
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Cell. 2021 Jan 7;184(1):149-168.e17
pubmed: 33278357
Diabetes Metab Syndr. 2021 May-Jun;15(3):863-868
pubmed: 33878674
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Nature. 2014 Jun 5;510(7503):58-67
pubmed: 24899305
EMBO Mol Med. 2021 Jan 11;13(1):e13424
pubmed: 33190411
Viruses. 2021 Jan 11;13(1):
pubmed: 33440724
Science. 2019 Oct 18;366(6463):
pubmed: 31624181
Cancers (Basel). 2020 Jun 15;12(6):
pubmed: 32549297
J Biol Chem. 2020 Nov 6;295(45):15174-15182
pubmed: 32917722
Clin Chim Acta. 2020 Oct;509:280-287
pubmed: 32531256
J Leukoc Biol. 2020 Jul;108(1):17-41
pubmed: 32534467
Nat Immunol. 2021 Jan;22(1):74-85
pubmed: 32999467
Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):12018-23
pubmed: 21715659
Nat Commun. 2020 Jul 6;11(1):3434
pubmed: 32632085
J Surg Res. 2017 Nov;219:354-359
pubmed: 29078905
Arch Med Res. 2020 Jul;51(5):384-387
pubmed: 32402576
Sci Rep. 2019 Mar 27;9(1):5272
pubmed: 30918324
Front Immunol. 2019 Jul 19;10:1706
pubmed: 31379883
Cell Death Dis. 2021 Mar 12;12(3):263
pubmed: 33712574
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
J Exp Med. 2013 Jun 3;210(6):1189-200
pubmed: 23712431
Biochimie. 2020 Dec;179:228
pubmed: 33161004
Immunity. 2011 Dec 23;35(6):972-85
pubmed: 22177921
Cell Physiol Biochem. 2019;53(6):1015-1028
pubmed: 31854953
JAMA. 2021 Apr 27;325(16):1603
pubmed: 33904860
Cell Metab. 2018 Jan 9;27(1):85-100.e8
pubmed: 29129787
Sci Transl Med. 2011 Oct 12;3(104):104ra100
pubmed: 21998407
Respir Res. 2020 Jul 6;21(1):171
pubmed: 32631317
Immunity. 2012 Mar 23;36(3):374-87
pubmed: 22425248
Toxicol Rep. 2020 Jun 18;7:768-771
pubmed: 32632359
Cell Physiol Biochem. 2016;38(6):2094-102
pubmed: 27184795
Nat Immunol. 2016 Apr;17(4):364-8
pubmed: 27002844
Nat Rev Immunol. 2020 May;20(5):269-270
pubmed: 32273594
Cell. 2016 Jun 30;166(1):63-76
pubmed: 27293185
Nat Immunol. 2013 Nov;14(11):1173-82
pubmed: 24076634
FASEB J. 2010 Apr;24(4):1229-38
pubmed: 20007509
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
iScience. 2021 Jun 25;24(6):102489
pubmed: 33969281
Eur J Immunol. 2013 Apr;43(4):889-96
pubmed: 23310952
Mol Genet Metab. 2008 Nov;95(3):133-41
pubmed: 18805722
SN Compr Clin Med. 2021 Apr 21;:1-7
pubmed: 33898924
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
Immunol Rev. 2012 Sep;249(1):27-42
pubmed: 22889213
Mol Immunol. 2020 Dec;128:64-68
pubmed: 33075636
Hypertension. 2021 Mar 3;77(3):846-855
pubmed: 33325240
J Clin Invest. 2013 Oct;123(10):4344-58
pubmed: 24091326
Adv Exp Med Biol. 2010;688:46-59
pubmed: 20919645
Nat Rev Cardiol. 2020 Sep;17(9):543-558
pubmed: 32690910
Lancet. 2021 Mar 13;397(10278):952-954
pubmed: 33581803
Mult Scler Relat Disord. 2020 Jul;42:102180
pubmed: 32408155
Immunity. 2020 Apr 14;52(4):583-589
pubmed: 32259480